Base-edited hematopoietic stem and progenitor cells + ALEMTUZUMAB + Busulfan + FILGRASTIM + PALIFERMIN + PLERIXAFOR for x-linked combined immunodeficiency diseases
A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set
Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.
Put together by software, not yet checked by a person